• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

芦可替尼治疗骨髓增生性肿瘤患者的非黑素瘤皮肤癌的结局和特征。

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.

机构信息

Haematology Department, University College London Hospital NHS Foundation Trust, London, United Kingdom.

Cancer Research UK Manchester Institute, Manchester, United Kingdom.

出版信息

Blood. 2024 Jan 11;143(2):178-182. doi: 10.1182/blood.2023022345.

DOI:10.1182/blood.2023022345
PMID:37963262
Abstract

Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.

摘要

接受鲁索替尼治疗的骨髓增生性肿瘤患者的非黑色素瘤皮肤癌 (NMSC) 具有侵袭性，表现为不良特征和高复发率。在我们的队列中，转移性 NMSC 的死亡率超过了骨髓纤维化。需要对皮肤进行密切评估、告知 NMSC 风险并开展鲁索替尼-NMSC 前瞻性研究。

相似文献

1
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.芦可替尼治疗骨髓增生性肿瘤患者的非黑素瘤皮肤癌的结局和特征。
Blood. 2024 Jan 11;143(2):178-182. doi: 10.1182/blood.2023022345.
2
A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.一项关于芦可替尼与真性红细胞增多症和骨髓纤维化患者非黑色素瘤皮肤癌相关性的10年回顾性队列研究。
J Am Acad Dermatol. 2022 Feb;86(2):339-344. doi: 10.1016/j.jaad.2021.10.004. Epub 2021 Oct 11.
3
Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.芦可替尼：骨髓纤维化患者的长期管理及骨髓增殖性肿瘤治疗的未来方向
Curr Hematol Malig Rep. 2014 Dec;9(4):350-9. doi: 10.1007/s11899-014-0229-y.
4
Aggressive cutaneous squamous cell carcinoma in a hydroxyurea- and ruxolitinib-pretreated patient with polycythaemia vera.羟基脲和芦可替尼预处理的真性红细胞增多症患者发生侵袭性皮肤鳞状细胞癌。
J Eur Acad Dermatol Venereol. 2022 Jan;36 Suppl 1:63-65. doi: 10.1111/jdv.17406.
5
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.芦可替尼的作用：了解分子发病机制和表观遗传失调如何影响骨髓增生性肿瘤的治疗效果。
J Transl Med. 2018 Dec 17;16(1):360. doi: 10.1186/s12967-018-1729-7.
6
Patient with eosinophilic dermatosis of myeloproliferative disease presenting with generalized erythematous plaques - Response to Ruxolitinib.患有骨髓增殖性疾病嗜酸性皮肤病并伴有全身性红斑斑块的患者——对鲁索替尼的反应
Australas J Dermatol. 2021 Nov;62(4):e613-e615. doi: 10.1111/ajd.13702. Epub 2021 Sep 7.
7
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.羟基脲耐药/不耐受的真性红细胞增多症患者接受芦可替尼或最佳可用疗法治疗后的主要临床结局的真实世界分析。
Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. Epub 2022 Apr 13.
8
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.接受鲁索替尼治疗的骨髓增殖性肿瘤患者对第一剂SARS-CoV-2疫苗接种反应受损。
Am J Hematol. 2021 Nov 1;96(11):E408-E410. doi: 10.1002/ajh.26305. Epub 2021 Aug 12.
9
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study.芦可替尼联合泼尼松、沙利度胺和达那唑治疗骨髓纤维化患者：一项初步研究的结果。
Hematol Oncol. 2022 Oct;40(4):787-795. doi: 10.1002/hon.3026. Epub 2022 May 28.
10
Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.骨髓增殖性肿瘤的生物学和临床管理以及 JAK 抑制剂芦可替尼的研发。
Curr Med Chem. 2012;19(26):4399-413. doi: 10.2174/092986712803251511.

引用本文的文献

1
USP5 inhibition via bone marrow-targeted engineered exosomes for myeloproliferative neoplasms therapy.通过骨髓靶向工程外泌体抑制USP5用于骨髓增殖性肿瘤治疗
J Nanobiotechnology. 2025 Jul 11;23(1):501. doi: 10.1186/s12951-025-03588-4.
2
Myelofibrosis: Treatment Options After Ruxolitinib Failure.骨髓纤维化：芦可替尼治疗失败后的治疗选择
Curr Oncol. 2025 Jun 9;32(6):339. doi: 10.3390/curroncol32060339.
3
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.
聚乙二醇干扰素α-2b在中国和日本真性红细胞增多症患者中的群体药代动力学-药效学及暴露-反应关系
Pharmacol Res Perspect. 2025 Jun;13(3):e70109. doi: 10.1002/prp2.70109.
4
Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey.真性红细胞增多症患者和医生对治疗期望及症状学的看法：来自里程碑2.0全球健康调查的见解
Hemasphere. 2025 Mar 24;9(3):e70106. doi: 10.1002/hem3.70106. eCollection 2025 Mar.
5
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.骨髓纤维化的靶向治疗：现状、正在进行的研究及未来展望
Am J Hematol. 2025 Jun;100 Suppl 4(Suppl 4):30-50. doi: 10.1002/ajh.27658. Epub 2025 Mar 10.
6
JAK Inhibitors for Myelofibrosis: Strengths and Limitations.JAK 抑制剂治疗骨髓纤维化：优势与局限。
Curr Hematol Malig Rep. 2024 Dec;19(6):264-275. doi: 10.1007/s11899-024-00744-9. Epub 2024 Oct 14.
7
JAK inhibitor selectivity: new opportunities, better drugs?JAK 抑制剂选择性：新机遇，更好的药物？
Nat Rev Rheumatol. 2024 Oct;20(10):649-665. doi: 10.1038/s41584-024-01153-1. Epub 2024 Sep 9.
8
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis.一项评估罗特西普干扰素 alfa-2b 在早期/低危原发性骨髓纤维化患者中的疗效和安全性的随机、双盲、安慰剂对照 3 期研究。
Ann Hematol. 2024 Sep;103(9):3573-3583. doi: 10.1007/s00277-024-05912-8. Epub 2024 Aug 15.